Background: The pathogenesis of idiopathic pulmonary arterial hypertension (IPAH) is unknown, and the syndrome of IPAH remains a diagnostic and therapeutic challenge. The present study investigated the disease-specific proteins that aid in the diagnosis of IPAH and thus to study their role in the disease process. Methods: A comparative proteomic analysis was used for clinical screening of serum proteins in 10 patients with IPAH and compared with 10 normal subjects. Furthermore, enzyme linked immunosorbent assay (ELISA) was performed for comparison with serum proteins between individual IPAH patients and controls. Results: Nine proteins and their isoforms, including leucine-rich a-2-glycoprotein (LRG), haptoglobin precursor, albumin isoform 2, transferrin variant, C3 complement, hydroxypyruvate reductase isoform 1, RAF1, fibrinogen isoformg-A and fibrinogen isoformg-B showed significant changes in serum of IPAH patients compared with controls by proteomic analysis. And significant higher serum levels of LRG in IPAH patients compared with controls were found by ELISA. Correlation analysis disclosed a significant association between serum LRG concentrations and New York Heart Association (NYHA) functional class (r Z 0.71, P < 0.01) and cardiac output (CO) (r Z À0.65, P < 0.01). a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / r m e d Respiratory Medicine (2009) 103, 1801e1806
Introduction
Idiopathic pulmonary arterial hypertension is a rare disease of unknown etiology characterized by progressive elevation of pulmonary arterial pressure (PAP). 1 Although there was a great improvement in survival with the development of new therapies, IPAH is still a condition with high mortality rates. The accurate assessment of prognosis in patients is difficult. Moreover, the optimal timing for invasive procedures such as atrial septostomy or lung transplantation remains controversial that leads to a high mortality rate among patients on the waiting lists. Many biomarkers have been proposed as prognostic indicators in IPAH, including uric acid, 2 troponin T, 3 big endothelin 4 and brain natriuretic peptide. 5 IPAH is characterized by abnormal muscularization of pulmonary arterioles, intimal thickening, and fibrosis, 6 as well as the presence of plexiform lesions, which are believed to result from dysregulation of endothelial cell growth. 7 Mutations of the bone morphogenetic protein receptor type II gene (BMPR2), a component of the transforming growth factor beta (TGF-b) family which plays a key role in cell growth, have been identified as causing familial and sporadic forms of idiopathic pulmonary arterial hypertension. 8, 9 Previous studies suggest that LRG interacts with TGF-b receptor and modulates the activity of TGF-b 10 and RAF proteins are a downstream response to growth factors including TGF-b1. 11 Proteomics is regarded as a complementary technology to genomics and can be used to analyze body fluids such as serum, urine, and cerebrospinal fluid. Proteomics offers a completely new methodology for the analysis of complicated biological and medical systems. The proteomic approach allows the parallel evaluation of a large number of components instead of just one or a few selected markers, and is free of the bias caused by the pre-selection of experimental targets. This is especially relevant if no definite pathological hypothesis has to be proved or disproved, but the aim is to attain a breakthrough in understanding physiological or pathological mechanisms. Two dimensional gel electrophoresis (2-DE) in combination with mass spectrometry (MS) has been widely used in cardiovascular fields. 12, 13 Here we describe our preliminary findings using proteomic analysis to study the changes in the expression of serum proteins in patients with IPAH. Our study found that simultaneous analysis of the expression of 10 protein spots could distinguish patients with IPAH from normal controls. Furthermore, we also present a sensitive immuno-assay on the level of LRG from patients with IPAH and controls and the link between the variation of LRG levels and clinical parameters.
Methods Patients
A total of 25 IPAH patients including 8 males and 17 females were included. The diagnosis of IPAH was established according to the criteria of the National Institute of Health registry. 1 All patients underwent right heart catheterization (RHC). Forty normal subjects were recruited as normal control with matched age and sex. Informed consent was obtained from each participant. The study was approved by the Institutional Review Boards of Fu Wai Hospital.
Serum samples
Blood samples were collected at baseline and were centrifuged shortly after clot formation. All samples were stored at À80 C in aliquots and thawed only before the test. The serum albumin and IgG were removed using the albumin and IgG removal kit (GE healthcare).
2-DE and MALDI-TOF-MS
To identify IPAH-specific proteins, serum samples from 10 patients with IPAH and 10 normal subjects were used. 2-DE and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) analysis were performed as described in the supplemental section.
Enzyme linked immunosorbent assay
LRG was measured in serum samples with commercially available sandwich ELISA kits (Quantikine, R&D Systems, Minneapolis, MN, USA), following the manufacturer's instructions. The result was interpolated from the standard reference curve provided with each kit. Each sample was tested in duplicate and thawed only once.
Statistical analysis
Data were shown as the mean AE standard deviation (SD) or as percentages. A 2-sided Student's t-test was used to evaluate different mean levels between two groups. The Pearson correlation coefficient was used to evaluate the correlation between the continuous variables. For all analysis, a 2-sided P-value < 0.05 was considered as statistically significant. All analyses were performed with the Statistical Package for Social Sciences for Windows (SPSS, Chicago, IL) version 14.0.
Results
The baseline haemodynamic pattern and the clinical characteristics of the 25 patients enrolled in the study are listed in Table 1 .
Comparison of the silver-stained gels of the serum samples from the 10 control subjects yielded almost identical protein expression profiles. The gels of the control and IPAH proteins were digitized and analyzed by PDQuest software. Comparison of the mean intensity of spots between the 10 IPAH and 10 control gels identified significant changes in 10 protein spots, representing 9 proteins. These proteins were identified by MS as leucine-rich a-2glycoprotein, haptoglobin precursor, albumin isoform 2, transferrin variant, C3 complement, hydroxypyruvate reductase isoform 1, RAF1, fibrinogen isoformg-A and fibrinogen isoformg-B. Two of them (haptoglobin and fibrinogen) were expressed as multiple spots on 2-D gels, suggesting that they were either charge isoforms or fragments of the same protein. The altered protein spots are highlighted in Fig. 1 and summarized in Table 2 .
Measurable levels of LRG were found in both the IPAH patients and the control subjects by the immunoenzymatic technique. In IPAH group, LRG level in serum was 234.6 AE 8.4 mg/mL (range, 189.3e345.2 mg/mL). In the control group, the LRG level was 52.3 AE 7.3 mg/mL (range, 32e75.4 mg/mL). Analysis of ELISA results indicates that the LRG levels in IPAH patients are significantly higher than the control subjects (P < 0.01) ( Fig. 2 ). Serum LRG concentration correlated with prognostically important variables, positively with NYHA functional class (r Z 0.71, P < 0.01), and inversely with right cardiac output (CO) (r Z À0.65, P < 0.01). Interestingly, no correlations between serum LRG concentration and meanPAP, pulmonary vascular resistance (PVR), pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), troponin T or uric acid were found in our group (Table 3 ).
Discussion
The present comparative proteomic approach based on silver staining and MALDI-TOF-MS identified 10 changed protein spots in the serum of patients with IPAH. Nine proteins and their isoforms, including leucine-rich a-2glycoprotein, haptoglobin precursor, albumin isoform 2, transferrin variant, C3 complement, hydroxypyruvate reductase isoform 1, RAF1, fibrinogen isoform g-A and fibrinogen isoform g-B, were affected. The subsequent analysis indicated that LRG concentrations were significantly higher in IPAH patients than the control subjects and correlated with NYHA functional class and cardiac output. These results suggest that the measurement of LRG, RAF1 and C3 complement levels in the serum may be helpful for the diagnosis of IPAH. In particular, LRG may be a specific prognostical biomarker of IPAH.
LRG was first identified as a trace protein in human serum. The primary sequence of LRG includes leucine rich repeat (LRR), a marked periodicity in the leucine residues in this protein. The function of LRG has not been elucidated, although the functions of many of the other members of the LRR-containing superfamily are known. Previous studies suggest that LRG interacts with TGFb receptor and modulates the activity of TGF-b. 10 Heterozygous germline mutations of BMPR2, a component of the TGF-b-related family, is found to underlie up to 60% of cases of familial IPAH. 8, 9 BMPR2 expression is documented in plexiform lesions 14 and in remodeled pulmonary arteries in IPAH lungs, predominantly in endothelial cells. Despite evidence supporting a loss of function for the TGF-b family signaling, particularly in endothelial cells of IPAH, TGFb may produce gain-of-function alterations underlying medial smooth muscle cell growth and adventitial fibroblast activation. TGF-b is expressed in hypertensive pulmonary arteries, 15 and could signal via activation of smad 2 or 3, whose expression was documented in pulmonary vascular smooth muscle cells. 16 TGF-b is known to increase the synthesis of collagen, profibrotic proteins and extracellular matrix protein production. 17 Changes in extracellular matrix composition contribute to progressive left ventricular remodeling. 18 Most importantly cardiac TGF-b has been shown to be increased in patients with myocardial infarction, dilated cardiomyopathy and hypertrophic cardiomyopathy, cardiac conditions that are all associated with increased heart failure. 19e21 These results suggest that LRG may be involved in the development of pulmonary hypertension and heart failure through a possible interaction with TGF-b. Increased levels of LRG in serum may be useful for identifying and monitoring the progression of IPAH.
Complement C3 is produced by endothelial cells, monocyte/macrophages, and fibroblasts. 22 C3 is increased in chronic inflammation and induces circulating monocytes to express tissue factor, which is a potent procoagulant. 23 In addition, C3d, a stable degradation product of C3b, plays a major role in instructing the adaptive immune response, 24 associated particularly with thrombosis. Under physiologic conditions, in situ complement activation contributes to the clearance of apoptotic cells from vascular lesions to prevent necrosis and vascular damage associated with thrombosis. In a pathologic setting, complement activation may enhance inflammation and influence the adaptive immune response in the arterial wall. Complement derived inflammatory mediators likely play a role in vascular injury. 25 In our proteomic study, complement C3 levels were increased in the serum from IPAH patients compared to control subjects. These results suggest that in vivo settings were in conditions with increased inflammation. Vascular pathology leading to thrombosis is influenced by several recognized risk factors including arterial injury, inflammation, and activation of the adaptive immune response. Vascular changes commonly seen in IPAH include medial hypertrophy, intimal hyperplasia, plexiform lesions, and small-vessel thrombi. Local pulmonary thrombosis, likely initiated by microscopic endothelial surface coagulation, is frequently observed in patients with IPAH. 26 RAF kinases were first discovered with the ability to induce growth and morphological transformation of established cell lines. Subsequently it was discovered that activation of RAF proteins is a downstream response to growth factors including TGF-b1 and is required to link growth factor receptor signaling to activation of gene expression. 11 RAF1 protein is one of 3 RAF isoforms in mammalians (ARAF, BRAF and CRAF or RAF1). The interaction between GTPase Ras and its downstream effector RAF1 is of crucial importance for the regulation of cell division and differentiation. 27 RAF1 has a critical role in controlling of cell cycle progression by acting through mitogen-activated protein kinases to induce protection against various apoptotic stimuli. 28 RAF1 upregulation may decrease apoptosis, resulting in proliferation of the endothelial cell. Future studies are needed to elucidate the pathophysiological role of RAF1 in IPAH.
However, the method used in this study cannot be used in clinical practice for the moment because of the high cost of this new approach. The expression of other proteins such as albumin isoform 2 (spot 2), hydroxypyruvate reductase isoform 1(spot 6), and transferrin variant (spot 9) are also altered in our patients. Their roles in the development of IPAH remain to be further investigated.
In conclusion, our results indicate that there are significant differences in the expression of proteins in the serum of patients with IPAH and normal subjects. And the measurement of LRG, RAF1 and C3 complement levels in the serum may be helpful for the diagnosis of IPAH. In particular, LRG may be a specific prognostical biomarker of IPAH.
Limitations
The present study has several limitations. First, cardiopulmonary exercise tests, particularly the 6-minute walk test, which is thought to be linked to IPAH patient prognosis, have not been performed. Second, the lack of currently available antibodies to RAF for ELISA has hindered the determination of its concentration in the serum and its pathophysiological role in IPAH. Further researches using antibody against RAF should help to elucidate the value of RAF. 
